Pain
Pain is a prominent symptom in ME/CFS, with approximately 80% of patients reporting significant pain in the past week (Unger et al. 2016).
1 Types of Pain in ME/CFS
Myalgia (Muscle Pain). Muscle pain is the most common pain complaint, affecting 72–94% of ME/CFS patients (Nijs, Meeus, et al. 2012). The pain is typically widespread rather than localized and characteristically worsens 8–72 hours following physical exertion as part of post-exertional malaise. Patients describe deep, aching pain that differs from delayed-onset muscle soreness in healthy individuals—it occurs following minimal exertion, lasts substantially longer, and is accompanied by other PEM symptoms. The pain reflects underlying skeletal muscle dysfunction including mitochondrial impairment, oxidative stress, reduced heat shock proteins, and impaired muscle contractility (Jammes et al. 2021).
Arthralgia (Joint Pain). Joint pain affects 58–84% of patients and is included as a criterion in both Fukuda and Canadian Consensus definitions (Fukuda et al. 1994) (Carruthers et al. 2003). The pattern is characteristically migratory (moving between joints) and occurs without the swelling, redness, warmth, or deformity seen in inflammatory arthritis. This distinction is clinically important: presence of joint inflammation suggests an alternative diagnosis or comorbid condition requiring separate evaluation.
Headaches. Headaches are significantly more common in ME/CFS than the general population: 84% experience migraine headaches (versus 5% in healthy controls) and 81% have tension-type headaches (versus 45% in controls) (Ravindran et al. 2011). The breakdown includes migraine without aura (60%), migraine with aura (24%), tension headaches only (12%), and no headaches (4%). ME/CFS patients with migraine demonstrate lower pressure pain thresholds (2.36 kg versus 5.23 kg in controls, p<0.001) and higher fibromyalgia comorbidity (47% versus 0%) (Ravindran et al. 2011). Headaches are listed in Fukuda criteria as one of eight minor symptoms.
Neuropathic Pain. A subset of ME/CFS patients experience neuropathic pain characterized by burning, tingling, or electric shock sensations. This correlates with the finding that 30–38% of ME/CFS patients have small fiber neuropathy (SFN) confirmed by skin biopsy demonstrating reduced intraepidermal nerve fiber density (Oaklander et al. 2022). Of those with confirmed SFN, 93% have comorbid postural orthostatic tachycardia syndrome (POTS) or other orthostatic intolerance, suggesting shared pathophysiology involving autonomic small fibers (Devigili et al. 2023).
2 Pain Mechanisms
Central Sensitization. Central sensitization—increased excitability of central nervous system pain pathways—is present in 84% of ME/CFS patients, compared to 95% of fibromyalgia patients and 0% of healthy controls (Nijs et al. 2021). This is defined by enhanced temporal summation (wind-up) combined with inefficient conditioned pain modulation. Clinical manifestations include:
- Generalized hyperalgesia to electrical, mechanical, heat, and chemical stimuli
- Affects multiple tissues including skin, muscle, and viscera
- Hyperalgesia augmented rather than decreased following exercise or other stressors
- Lower pressure pain thresholds: ME/CFS median 222 kPa versus healthy controls 311 kPa (p<0.05) (Nijs et al. 2021)
Central sensitization is driven by neuroinflammation—glial cell activation (microglia and astrocytes) in the spinal cord and brain releasing pro-inflammatory cytokines and chemokines that sustain neural hypersensitivity (Nijs et al. 2017).
Small Fiber Neuropathy. Small fiber neuropathy provides an objective, biopsy-confirmed mechanism for pain in a substantial subset of patients. Studies find 30–38% of ME/CFS patients meet diagnostic criteria for SFN (Oaklander et al. 2022). Small fibers (A-delta and C fibers) mediate pain, temperature sensation, and autonomic function, explaining the overlap between pain and dysautonomia. The etiology of SFN in ME/CFS is not fully established but may involve autoimmune mechanisms, as autoantibodies against small fiber antigens have been identified in some patients.
Peripheral Mechanisms. Peripheral contributors to ME/CFS pain include:
- Elevated blood lactate: Nearly half of ME/CFS patients have elevated resting lactate levels, correlating with more severe post-exertional malaise (Lien et al. 2019). Lactate accumulation reflects anaerobic metabolism predominance due to mitochondrial dysfunction.
- Metabolic dysfunction: Impaired ATP synthesis leads to toxic metabolite accumulation that activates muscle nociceptors (Jammes et al. 2021).
- Impaired proton handling: Profound intramuscular acidosis develops following minimal exertion.
- Reduced oxygen delivery: Endothelial dysfunction and microvascular abnormalities may limit oxygen supply to exercising muscles.
Relationship to Post-Exertional Malaise. Pain is a core component of PEM. A meta-analysis found small to moderate pain increases following exercise in ME/CFS versus controls (Hedges’ d = 0.42, 95% CI: 0.16–0.67), with delayed pain showing larger effects at 8–72 hours (d = 0.71) than at 0–2 hours (d = 0.32) (Barhorst et al. 2022). This delayed, disproportionate pain response parallels the temporal pattern of other PEM symptoms and likely reflects the same underlying metabolic and immune dysfunction. Factor analysis of PEM symptoms identifies a distinct “musculoskeletal factor” comprising muscle pain, weakness, and post-exertional fatigue (Barhorst et al. 2022).
3 Patient-Reported Pain Descriptions
Qualitative research and standardised pain inventories reveal a distinctive pain language in ME/CFS. On the McGill Pain Questionnaire (MPQ), patients most frequently selected the sensory descriptors throbbing, aching, tender, gnawing, and burning; severely affected patients additionally endorsed exhausting, nagging, and gruelling (Marshall et al. 2010). The mean Pain Rating Index was 23.6 ± 10.8, with current visual analogue scale (VAS) intensity of 43.2 ± 20.8 mm; 24-hour retrospective VAS was higher (~58 mm), reflecting the fluctuating nature of ME/CFS pain (Marshall et al. 2010). Pain Anxiety Symptoms Scale scores (37.9 ± 17.6) were significantly elevated in severely disabled patients.
Patients describe their pain experience in language that clinicians should recognise as distinctive (Marshall et al. 2010) (Strassheim, Newton, and Collins 2021):
- Muscle pain characterised as deep, bone-aching or burning, migratory rather than fixed, and qualitatively different from delayed-onset muscle soreness (consistent with MPQ descriptors aching, burning, gnawing)
- Post-exertional pain experienced as systemic malaise—language reflecting the sickness-behaviour quality of PEM-associated pain rather than focal injury
- Neuropathic sensations including electric, pins-and-needles, or burning-skin quality, consistent with the 30–38% SFN prevalence (Oaklander et al. 2022)
- Pain that moves unpredictably between body regions, consistent with the migratory joint pain pattern documented across cohorts (Carruthers et al. 2003)
Most common pain locations by body mapping (Margolis Body Chart): cervical spine (66%), anterior thighs (44–46%), lumbar spine (42%), and posterior calves (38%). The most severe pain clusters in the cervical spine/upper trapezius (30%), scapular/upper thoracic region (20%), and right lumbar area (20%) (Marshall et al. 2010).
4 Pain Phenotype Classification
ME/CFS pain is not monolithic. The MCAM study (Multi-site Clinical Assessment of ME/CFS; \(n = 595\) ME/CFS patients, 328 healthy controls across 7 US specialty clinics, 2012–2020) documented that 76.1% of ME/CFS participants had at least one Chronic Overlapping Pain Condition (COPC), compared to 17.4% of controls (Fall et al. 2024). Prevalence ratios versus controls were striking: fibromyalgia 147.7\(\\times\), chronic low back pain 39.5\(\\times\), interstitial cystitis/painful bladder syndrome 13.8\(\\times\), and chronic migraine 4.2\(\\times\) (Fall et al. 2024).
Six clinically relevant pain phenotypes can be distinguished, though most patients exhibit combinations:
- Widespread musculoskeletal pain (68–94%): The most common complaint. Deep aching in muscles and periarticular tissues, characteristically worsening 8–72 hours post-exertion (Nijs, Meeus, et al. 2012) (Barhorst et al. 2022).
- Headache-predominant (48–56%): Including chronic migraine (48.1% in MCAM) and tension-type headache, often with lower pressure pain thresholds (Ravindran et al. 2011) (Fall et al. 2024).
- Neuropathic pain (30–80%): Burning, tingling, electric shock sensations; prevalence range reflects variability in SFN diagnostic methods and whether fibromyalgia-overlapping cohorts are included (Oaklander et al. 2022) (Grayston et al. 2019).
- Post-exertional pain flare: Delayed pain amplification prominent in ME/CFS—pain increases significantly at 8–72 hours post-exercise (Hedges’ \(d = 0.71\)) versus 0–2 hours (\(d = 0.32\)) (Barhorst et al. 2022). Whether this pattern differs in FM-only patients awaits direct head-to-head comparison (Barhorst meta-analysis pools ME/CFS and FM cohorts).
- Allodynia and hyperalgesia: Pain from normally non-painful stimuli (light touch, clothing pressure, temperature changes) and amplified pain response to mildly painful stimuli, reflecting central sensitisation (Nijs et al. 2021).
- Visceral and other pain: Abdominal pain (32%), sore throat (25–28%), tender lymph nodes (37–39%), eye pain (23%), chest pain (15%) (Fall et al. 2024) (Unger et al. 2016).
The dominant mechanism underlying most ME/CFS pain phenotypes is increasingly characterized as nociplastic—arising from altered nociception in the central nervous system despite no clear evidence of peripheral tissue damage (Kosek 2024) (Chen et al. 2025). However, 30–38% of patients have biopsy-confirmed small fiber neuropathy by standardised criteria (Oaklander et al. 2022) (with higher estimates up to 80% when fibromyalgia-overlapping cohorts and less standardised methods are included (Grayston et al. 2019)), contributing a neuropathic component. The interaction between nociplastic and neuropathic mechanisms likely produces a hybrid pain phenotype (see ME/CFS Pain as Nociplastic-Neuropathic Hybrid). Central sensitisation involves dysfunction of midbrain and brainstem descending anti-nociceptive pathways, where the periaqueductal grey and medulla fail to send adequate inhibitory signals. See Central Sensitization and Nociplastic Pain for detailed mechanistic discussion.
5 Pain Assessment and Management Considerations
5.1 Quantitative Pain Assessment
Multiple validated instruments have been applied to ME/CFS pain, though none was designed for this population. A 2025 comparative review of assessment scales concluded that the McGill Pain Questionnaire is preferred for ME/CFS because it is “sensitive to treatment-related changes and useful for distinguishing nociceptive and neuropathic pain” (Lu et al. 2025).
Key quantitative findings across instruments:
- McGill Pain Questionnaire (MPQ): Pain Rating Index 23.6 ± 10.8; significantly higher in severely disabled patients (\(p < 0.05\)) (Marshall et al. 2010)
- Visual Analogue Scale (VAS): Current intensity 43.2 mm; 24-hour retrospective ~58 mm (better reflects fluctuating pain) (Marshall et al. 2010)
- Brief Pain Inventory (BPI): ME/CFS patients with chronic low back pain show BPI Interference mean difference = 3.77 (Cohen’s \(d = 1.6\)); those with comorbid fibromyalgia show mean difference = 2.39 (\(d = 0.9\)) (Fall et al. 2024)
- Dolorimetry: Female ME/CFS patients AUC = 0.730 versus controls (\(p < 0.005\)); male patients AUC = 0.816 (\(p < 10^{-6}\)). Dolorimetry correlates with self-reported pain (Spearman \(R = -0.574\) to \(-0.629\), \(p < 0.001\)) (Chen et al. 2025)
- Quantitative sensory testing (QST): Pressure pain thresholds at standard sites, thermal thresholds, and temporal summation protocols can objectively document pain hypersensitivity and support disability claims (Nijs et al. 2021) (Chen et al. 2025)
Pain interference in ME/CFS reaches levels comparable to spinal cord injury, muscular dystrophy, and multiple sclerosis (Fall et al. 2024).
The NINDS Common Data Elements (CDE) Pain Subgroup recommended existing generic instruments (BPI Short Form, Revised Fibromyalgia Impact Questionnaire, MPQ) for ME/CFS research but explicitly identified that no ME/CFS-specific pain instrument exists (Lu et al. 2025). Three unmet needs were flagged: (1) an instrument measuring both pain and PEM together, since PEM-delayed pain onset is a pattern currently documented primarily in ME/CFS; (2) a tool for capturing multiple overlapping pain conditions simultaneously; and (3) a method for quantitatively assessing ME/CFS pain comparably across chronic pain conditions. Until such instruments are developed, the MPQ or Numeric Rating Scale (NRS) remain the recommended primary tools.
5.2 Overlap with Fibromyalgia
ME/CFS and fibromyalgia show substantial clinical overlap: 47.3% (95% CI: 45.97–48.63) of ME/CFS diagnoses overlap with fibromyalgia, with 35–75% of ME/CFS patients meeting fibromyalgia criteria and 20–70% of fibromyalgia patients meeting ME/CFS criteria (Ramirez-Morales et al. 2022). Cerebrospinal fluid proteomics are indistinguishable between ME/CFS patients with and without comorbid fibromyalgia, consistent with shared central pathophysiology (Nilsson et al. 2023). Key clinical distinctions:
- Symptom primacy: Fibromyalgia—pain predominant, fatigue secondary; ME/CFS—fatigue and PEM predominant, pain prominent but not defining
- Exercise response: The critical discriminator. In fibromyalgia, graded aerobic exercise can improve pain over time; in ME/CFS, exercise triggers immune activation (ASIC3, P2X4, TLR4 upregulation persisting 48 hours) and worsens pain through PEM (Nijs, Crombez, et al. 2012) (Barhorst et al. 2022). Prescribing graded exercise to an ME/CFS patient based on FM protocols risks serious harm.
- Pain timing: FM pain is relatively constant; ME/CFS pain characteristically flares 24–48 hours after exertion in the PEM pattern
- Analgesic response: FM is partially responsive to duloxetine and pregabalin; standard NSAIDs are frequently reported as ineffective in ME/CFS
- Substance P: Elevated in FM cerebrospinal fluid but not in ME/CFS, suggesting different neurochemical profiles despite shared nociplastic features (Chen et al. 2025)
- Comorbid patients have worse outcomes: greater physical disability, more severe pain, and more pronounced post-exertional symptoms than either condition alone
A parsimonious alternative to a distinct ME/CFS pain mechanism is that ME/CFS pain reflects fibromyalgia-spectrum nociplastic pain plus PEM, without requiring a novel pain pathway. If this alternative is correct, the clinical implications are limited: treatment would still target FM-type pain (central sensitisation, SFN) and PEM separately, rather than a unified ME/CFS-specific pain mechanism. The Barhorst 2022 meta-analysis pooled ME/CFS and FM cohorts, preventing extraction of ME/CFS-specific pain effect sizes. No study has directly compared exercise-pain responses in ME/CFS versus FM-only patients matched for baseline pain. The Substance P null finding (elevated in FM but not ME/CFS (Chen et al. 2025)) provides one point of divergence, but a single biomarker difference does not establish distinct mechanisms. Resolving this question requires a head-to-head exercise-pain study with ME/CFS, FM-only, and ME/CFS+FM groups.
Falsifiability: Pain should worsen 8–72h post-exertion in ME/CFS but not in FM-only patients matched for baseline pain severity; ASIC3/P2X4/TLR4 gene expression should correlate with delayed pain scores in ME/CFS but not FM; CPM efficiency should decrease post-exertionally in ME/CFS but not FM. — Partially supported by Barhorst 2022 meta-analysis and Nijs 2012 gene expression data; direct head-to-head comparison of exercise-pain response in ME/CFS vs FM-only is lacking.
The delayed, disproportionate pain amplification following exertion is a prominent feature of ME/CFS, potentially distinguishable from FM pending direct head-to-head comparison. Unlike FM, where pain can improve with graded exercise, ME/CFS exercise triggers a cascade of immune gene upregulation (ASIC3, P2X4, TLR4) that persists for 48 hours and correlates with pain severity (Nijs, Crombez, et al. 2012). Simultaneously, conditioned pain modulation (CPM)—the body’s endogenous pain inhibition—fails to activate and may paradoxically worsen after exercise in ME/CFS (Nijs, Meeus, et al. 2012). This PEM-pain amplification loop is mechanistically distinct from central sensitisation alone. However, a parsimonious alternative—that ME/CFS pain is simply FM plus PEM, without a distinct pain mechanism—has not been formally excluded. (Certainty: 0.45; meta-analytic evidence for delayed pain effect, but Barhorst 2022 pools ME/CFS and FM cohorts, preventing ME/CFS-specific effect extraction; gene expression evidence for immune mechanism; direct FM comparison lacking.)
5.3 Treatment Implications
Pain management in ME/CFS must account for the underlying mechanisms:
- Standard analgesics may be insufficient given central sensitisation (Nijs et al. 2021)
- Interventions targeting neuroinflammation (e.g., low-dose naltrexone) may address central mechanisms (Nijs et al. 2017)
- Activity pacing prevents pain exacerbation from PEM (Barhorst et al. 2022)
- Treatment of underlying small fiber neuropathy (if present) with IVIG has shown benefit in some patients (Oaklander et al. 2022). Caveats: IVIG requires specialist supervision, costs $10,000–30,000/year, carries infusion-related risks, and should be reserved for patients with biopsy-confirmed SFN; interaction with comorbid POTS must be monitored during infusion
- Medications effective for fibromyalgia pain (duloxetine, pregabalin) may help the subset with overlapping presentations (Fall et al. 2024)